Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 4 Interventional

The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts (ASAP-SVG) Pilot Trial

ClinicalTrials.gov ID: NCT03542110

Public ClinicalTrials.gov record NCT03542110. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 26, 2026, 3:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Effect of Alirocumab on Saphenous Vein Graft Atherosclerosis: The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts (ASAP-SVG) Pilot Trial

Study identification

NCT ID
NCT03542110
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 4
Lead sponsor
Minneapolis Heart Institute Foundation
Other
Enrollment
46 participants

Conditions and interventions

Interventions

  • Alirocumab 150 MG/ML subcutaneous injection Drug
  • Matching Placebo subcutaneous injection Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 3, 2018
Primary completion
Jun 29, 2020
Completion
Jul 30, 2020
Last update posted
Sep 15, 2021

2018 – 2020

United States locations

U.S. sites
4
U.S. states
4
U.S. cities
4
Facility City State ZIP Site status
San Francisco VA Medical Center San Francisco California 94121
Atlanta VA Medical Center Atlanta Georgia 30033
Minneapolis Heart Institute/ Abbott North Western Hospital-Allina Health Minneapolis Minnesota 55407
Dallas VA Medical Center Dallas Texas 75216

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03542110, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 15, 2021 · Synced Jun 26, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03542110 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →